{
    "startDate": "2018-01-01",
    "endDate": "2018-03-31",
    "year": "2018",
    "quarter": "Q1",
    "symbol": "SNSS",
    "data": {
        "bs": [
            {
                "label": "Cash and cash equivalents",
                "concept": "CashAndCashEquivalentsAtCarryingValue",
                "unit": "usd",
                "value": 21365000
            },
            {
                "label": "Marketable securities",
                "concept": "MarketableSecuritiesCurrent",
                "unit": "usd",
                "value": 4033000
            },
            {
                "label": "Prepaids and other current assets",
                "concept": "PrepaidExpenseAndOtherAssetsCurrent",
                "unit": "usd",
                "value": 1480000
            },
            {
                "label": "Current assets:",
                "concept": "AssetsCurrent",
                "unit": "usd",
                "value": 26878000
            },
            {
                "label": "Property and equipment, net",
                "concept": "PropertyPlantAndEquipmentNet",
                "unit": "usd",
                "value": 18000
            },
            {
                "label": "Other assets",
                "concept": "OtherAssetsNoncurrent",
                "unit": "usd",
                "value": 96000
            },
            {
                "label": "ASSETS",
                "concept": "Assets",
                "unit": "usd",
                "value": 26992000
            },
            {
                "label": "Accounts payable",
                "concept": "AccountsPayableCurrent",
                "unit": "usd",
                "value": 1038000
            },
            {
                "label": "Carrying value as of the balance sheet date of obligations incurred through that date and payable, pertaining to costs that are related to clinical trials for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
                "concept": "snss:AccruedClinicalExpenseCurrent",
                "unit": "usd",
                "value": 570000
            },
            {
                "label": "Accrued compensation",
                "concept": "EmployeeRelatedLiabilitiesCurrent",
                "unit": "usd",
                "value": 862000
            },
            {
                "label": "Other accrued liabilities",
                "concept": "OtherAccruedLiabilitiesCurrent",
                "unit": "usd",
                "value": 1905000
            },
            {
                "label": "Notes payable",
                "concept": "NotesPayableCurrent",
                "unit": "usd",
                "value": 7252000
            },
            {
                "label": "Current liabilities:",
                "concept": "LiabilitiesCurrent",
                "unit": "usd",
                "value": 11627000
            },
            {
                "label": "Commitments",
                "concept": "CommitmentsAndContingencies",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Convertible preferred stock",
                "concept": "PreferredStockValue",
                "unit": "usd",
                "value": 20966000
            },
            {
                "label": "Common stock",
                "concept": "CommonStockValue",
                "unit": "usd",
                "value": 3000
            },
            {
                "label": "Additional paid-in capital",
                "concept": "AdditionalPaidInCapital",
                "unit": "usd",
                "value": 634528000
            },
            {
                "label": "Accumulated other comprehensive loss",
                "concept": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
                "unit": "usd",
                "value": -5000
            },
            {
                "label": "Accumulated deficit",
                "concept": "RetainedEarningsAccumulatedDeficit",
                "unit": "usd",
                "value": -640127000
            },
            {
                "label": "Stockholders\u2019 equity:",
                "concept": "StockholdersEquity",
                "unit": "usd",
                "value": 15365000
            },
            {
                "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
                "concept": "LiabilitiesAndStockholdersEquity",
                "unit": "usd",
                "value": 26992000
            }
        ],
        "cf": [
            {
                "label": "Net loss",
                "concept": "NetIncomeLoss",
                "unit": "usd",
                "value": -7273000
            },
            {
                "label": "Stock-based compensation expense",
                "concept": "ShareBasedCompensation",
                "unit": "usd",
                "value": 896000
            },
            {
                "label": "Depreciation and amortization",
                "concept": "DepreciationDepletionAndAmortization",
                "unit": "usd",
                "value": 2000
            },
            {
                "label": "Amortization of debt discount and debt issuance costs",
                "concept": "AmortizationOfFinancingCostsAndDiscounts",
                "unit": "usd",
                "value": 48000
            },
            {
                "label": "Prepaids and other assets",
                "concept": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
                "unit": "usd",
                "value": -988000
            },
            {
                "label": "Accounts payable",
                "concept": "IncreaseDecreaseInAccountsPayable",
                "unit": "usd",
                "value": -659000
            },
            {
                "label": "The net change during the reporting period in the obligations incurred and payable, pertaining to costs that are related to clinical trials for which invoices have not yet been received or will not be rendered.",
                "concept": "snss:IncreaseDecreaseInAccruedClinicalExpense",
                "unit": "usd",
                "value": -197000
            },
            {
                "label": "Accrued compensation",
                "concept": "IncreaseDecreaseInEmployeeRelatedLiabilities",
                "unit": "usd",
                "value": -578000
            },
            {
                "label": "Other accrued liabilities",
                "concept": "IncreaseDecreaseInOtherAccruedLiabilities",
                "unit": "usd",
                "value": 223000
            },
            {
                "label": "Cash flows from operating activities",
                "concept": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
                "unit": "usd",
                "value": -6550000
            },
            {
                "label": "Proceeds from maturities of marketable securities",
                "concept": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
                "unit": "usd",
                "value": 742000
            },
            {
                "label": "Cash flows from investing activities",
                "concept": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
                "unit": "usd",
                "value": 742000
            },
            {
                "label": "Proceeds from issuance of common stock through equity facilities net.",
                "concept": "snss:ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet",
                "unit": "usd",
                "value": 32000
            },
            {
                "label": "Proceeds from the exercise of warrants, stock options and stock purchase rights.",
                "concept": "snss:ProceedsFromExerciseOfWarrantsStockOptionsAndStockPurchaseRights",
                "unit": "usd",
                "value": 164000
            },
            {
                "label": "Cash flows from financing activities",
                "concept": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
                "unit": "usd",
                "value": 196000
            },
            {
                "label": "Net increase (decrease) in cash and cash equivalents",
                "concept": "CashAndCashEquivalentsPeriodIncreaseDecrease",
                "unit": "usd",
                "value": -5612000
            }
        ],
        "ic": [
            {
                "label": "Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark (i.e. 'intellectual property'). Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. This element includes (i) licensing revenue recognized in the period under licensing arrangements (as opposed to revenues in connection with a larger collaboration or multiple-deliverable agreement), (ii) revenues recognized from the outright sale of intellectual property, (iii) the recognition of previously deferred revenue, and (iv) any other revenues not separately presented elsewhere in the statements of operations and comprehensive income (loss).",
                "concept": "snss:LicenseAndOtherRevenue",
                "unit": "usd",
                "value": 237000
            },
            {
                "label": "Revenue:",
                "concept": "Revenues",
                "unit": "usd",
                "value": 237000
            },
            {
                "label": "Research and development",
                "concept": "ResearchAndDevelopmentExpense",
                "unit": "usd",
                "value": 3969000
            },
            {
                "label": "General and administrative",
                "concept": "GeneralAndAdministrativeExpense",
                "unit": "usd",
                "value": 3359000
            },
            {
                "label": "Operating expenses:",
                "concept": "OperatingExpenses",
                "unit": "usd",
                "value": 7328000
            },
            {
                "label": "Loss from operations",
                "concept": "OperatingIncomeLoss",
                "unit": "usd",
                "value": -7091000
            },
            {
                "label": "Interest expense",
                "concept": "InterestExpense",
                "unit": "usd",
                "value": 281000
            },
            {
                "label": "Other income, net",
                "concept": "OtherNonoperatingIncomeExpense",
                "unit": "usd",
                "value": 99000
            },
            {
                "label": "Net loss",
                "concept": "NetIncomeLoss",
                "unit": "usd",
                "value": -7273000
            },
            {
                "label": "Unrealized gain on available-for-sale securities",
                "concept": "AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax",
                "unit": "usd",
                "value": 2000
            },
            {
                "label": "Comprehensive loss",
                "concept": "ComprehensiveIncomeNetOfTax",
                "unit": "usd",
                "value": -7271000
            },
            {
                "label": "Shares used in computing net loss per common share",
                "concept": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
                "unit": "shares",
                "value": 34345000
            },
            {
                "label": "Basic and diluted loss per common share:",
                "concept": "EarningsPerShareBasicAndDiluted",
                "unit": "usd/shares",
                "value": -0.21
            }
        ]
    }
}